StockNews.AI
SNY
StockNews.AI
74 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

1. Pomerantz LLP investigates potential securities fraud involving Sanofi officials. 2. Sanofi's recent Phase 3 trial results for itepekimab were mixed. 3. ADR price fell 5.69% following negative trial data release. 4. Investors are advised to contact Pomerantz for potential law claims.

3m saved
Insight
Article

FAQ

Why Bearish?

The investigation into Sanofi raises concerns about potential misconduct affecting investor confidence. Previous cases of similar nature led to significant declines in stock prices.

How important is it?

The investigation implies serious allegations that could lead to substantial financial and reputational damage. Such scrutiny can decrease investor trust, impacting stock performance significantly.

Why Short Term?

The ongoing investigation and its immediate effects can create volatility. Recent shareholder actions could lead to further price instability in the near term.

Related Companies

AMGNABBVBMY
NEW YORK, June 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi (“Sanofi” or the “Company”) (NASDAQ: SNY).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.    The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease.  Although the AERIFY-1 late-stage trial met the primary endpoint with a statistically significant and clinically meaningful impact, the AERIFY-2 trial failed to reach the same goal.  On this news, Sanofi’s American Depositary Receipt (“ADR”) price fell $2.98 per ADR, or 5.69%, to close at $49.37 per ADR on May 30, 2025. The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com. Attorney advertising.  Prior results do not guarantee similar outcomes.     CONTACT:Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News